Emerging platforms make it feasible for hepatitis C testing to be conducted in settings that within or outside of health care facilities, such as prisons.
All News
Advertisement
SUBA-itraconazole is indicated for the treatment of blastomycosis, pulmonary and extrapulmonary; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis; and aspergillosis, pulmonary and extrapulmonary.
Advertisement
The FDA has approved Mayne Pharma Group Limited’s New Drug Application for SUBA-itraconazole (Tolsura) 65mg capsules.
New study data reinforce the long-term efficacy and safety of Amgen’s evolocumab (Repatha) in individuals at risk for heart attack and stroke, but an additional analysis highlights challenges associated with use of lipid-lowering therapies (LLTs) in these patients.
A patient-centric approach is vital to effective specialty pharmacy services.
Study shows that routinely screening inmates for hepatitis C virus at entry may identify a significant number of cases that would have been missed through targeted testing.
Advertisement
Top news of the day across the health care landscape.
Top news of the day across the health care landscape
Experts argue whether a decline in cognitive function should lead to a change in disease-modifying therapy for multiple sclerosis.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
3
Strengthening Neurology Care Through Clinical Pharmacy Integration and Collaborative Practice
4
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
5